EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Clinical Pharmacology and Translational Science Considerations in the Development of Dual‐Payload Antibody Drug Conjugates

Paulien Ravenstijn iD, Toru Kakinuma iD, Salaheldin Hamed iD, Takeshi Kadokura iD, Yohei Okada iD, Srinivasu Poondru

Clinical and Translational Science · 2026-05 · 19 (5)

DOI: 10.1111/cts.70569 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, online erschienen am 06.05.2026. Verfasst von Paulien Ravenstijn und 5 weiteren Autor:innen. Beteiligte Einrichtung: Astellas Pharma Europe BV, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Immunoconjugates, Neoplasms, Translational Science, Biomedical, Pharmacology, Clinical. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody‐drug conjugates (ADCs) have evolved in the last decade or two from carrying a single chemotherapy payload to carrying highly potent tubulin inhibitors and DNA damaging agents. While the latter have shown success in the clinic, efficacy has been constrained by therapeutic resistance, limited tumor penetration, and suboptimal immune activation. Currently, the ADC development space also includes the development of tumor‐targeting monoclonal antibodies that carry dual‐payloads, incorporating both cytotoxic agents and, for example, immunostimulatory molecules that could synergize direct tumor cell killing with reprogramming of the tumor immune microenvironment (TME). The translational and clinical pharmacology development strategy for ADCs is complicated by the need to understand the mechanism of action (MoA), the pharmacokinetics, and the pharmacodynamics of the different components of the ADC, and this gets even more complicated when two payloads are in play. The challenge lies, for instance, in understanding the MoA of each payload and the resulting synergy in effect, the increased number of analytes for bioanalysis, and the potential for added anti‐drug antibody (ADA) formation due to more available epitopes in the ADC that could be recognized by the immune system. To date, no dual‐payload ADCs have been approved, and this review is therefore intended to provide an overview on the translational science and clinical pharmacology strategies in the development of ADCs with two or more payloads based on what is currently known and published about single‐payload ADCs and the authors' perspective.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesNeoplasmsTranslational Science, BiomedicalPharmacology, ClinicalDrug DevelopmentHumansTumor MicroenvironmentAnimalsTranslational Research, BiomedicalAntineoplastic Agents

Stichwörter der Autor:innen

antibody‐drug conjugateclinical pharmacologydual‐payloadimmune‐oncologyoncologytranslational science

Substanzen

ImmunoconjugatesAntineoplastic Agents

Autor:innen und Institutionen

  • Astellas Pharma Europe BV, Leiden, the Netherlands.
  • Astellas Pharma Inc, Tokyo, Japan.
  • Astellas Pharma Global Development, Inc, Northbrook, Illinois, USA.

ORCID-Profile: Paulien Ravenstijn, Toru Kakinuma, Salaheldin Hamed, Takeshi Kadokura, Yohei Okada

Zitieren

APA

Ravenstijn, P., Kakinuma, T., Hamed, S., Kadokura, T., Okada, Y., & Poondru, S. (2026). Clinical Pharmacology and Translational Science Considerations in the Development of Dual‐Payload Antibody Drug Conjugates. Clinical and Translational Science, 19(5). https://doi.org/10.1111/cts.70569

Vancouver

Ravenstijn P, Kakinuma T, Hamed S, Kadokura T, Okada Y, Poondru S. Clinical Pharmacology and Translational Science Considerations in the Development of Dual‐Payload Antibody Drug Conjugates. Clinical and Translational Science. 2026;19(5). doi:10.1111/cts.70569

BibTeX
@article{Ravenstijn2026,
  author = {Ravenstijn, Paulien and Kakinuma, Toru and Hamed, Salaheldin and Kadokura, Takeshi and Okada, Yohei and Poondru, Srinivasu},
  title = {Clinical Pharmacology and Translational Science Considerations in the Development of Dual‐Payload Antibody Drug Conjugates},
  journal = {Clinical and Translational Science},
  year = {2026},
  volume = {19},
  number = {5},
  doi = {10.1111/cts.70569}
}
Kostenlos starten →